| Z04455 | |
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Conjugate | Biotin | ||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 92.38 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 100-120 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS, 100mM Arginine (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
| Target Background | FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent. |
| Synonyms | FcR-like protein 5; FcRH5; FcRL5; BXMAS1; BXMAS1MGC119592; CD307; CD307e; DKFZp667E2019; DKFZp667F216; FCRH5MGC119593; FLJ00333; FLJ00397; IFGP5; IRTA2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
